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Background: Nitric oxide in exhaled air (FENO) is a marker of eosinophilic airway inflammation. A study
was undertaken to determine whether FENO predicts asthma relapse in asymptomatic asthmatic children in
whom inhaled corticosteroids are discontinued.
Methods: Forty children (21 boys) of mean age 12.2 years on a median dose of 400 mg budesonide or
equivalent (range 100–400) were included. FENO was measured before and 2, 4, 12, and 24 weeks after
withdrawal of steroids. A relapse was defined as more than one exacerbation per month, or need for b
agonist treatment on 4 days per week for at least 2 weeks, or diurnal peak flow variability of.20%. FENO
measurements were performed online with an expiratory flow of 50 ml/s.
Results: Nine patients relapsed. Two and 4 weeks after withdrawal of steroids geometric mean FENO in
children who were about to relapse was higher than in those who did not relapse: 35.3 ppb v 15.7 ppb at
2 weeks (ratio 2.3; 95% CI 1.2 to 4.1; p = 0.01) and 40.8 ppb v 15.9 ppb at 4 weeks (ratio 2.6; 95% CI
1.3 to 5.1). An FENO value of 49 ppb at 4 weeks after discontinuation of steroids had the best
combination of sensitivity (71%) and specificity (93%) for asthma relapse.
Conclusion: FENO 2 and 4 weeks after discontinuation of steroids in asymptomatic asthmatic children may
be an objective predictor of asthma relapse.
R
emission of asthma is common in children.1 2 It is
difficult to determine the time point at which to reduce
or stop inhaled corticosteroids (ICS). ICS are currently
adapted on clinical grounds with dose reduction based on
patient history, sometimes influenced by parental or doctor’s
fears of side effects. However, there are few if any objective
means to guide parents or children. According to current
practice, ICS are discontinued in asthmatic children who are
symptom-free for at least 6 months on a low dose of inhaled
steroids. Follow up is discontinued soon after withdrawal of
ICS. However, some of these children will have a relapse, and
there is currently no objective parameter to predict the
probability of asthma relapse following steroid withdrawal.
Measurement of the fractional nitric oxide concentration in
exhaled air (FENO) has been proposed as a marker of
eosinophilic airway inflammation.3 4 FENO levels can be
obtained easily and repeatedly with minimal discomfort to
the patient, and measurement techniques have been well
standardised.4 5 Treatment with ICS reduces FENO by a direct
effect on transcription of inducible NO synthase and by
reducing airway inflammation.6–8 Even low doses of ICS may
decrease FENO to normal levels.
6 9–13 If FENO could give
additional information on the risk of asthma relapse, this
could potentially modify current treatment strategies. Only a
few studies have addressed the use of FENO as a predictor of
loss of asthma control related to changes in the ICS dose in
adults, and the results are unequivocal.11 14 15 The aim of this
study was to evaluate whether or not FENO predicts the
probability of asthma relapse in children in whom ICS are
discontinued because of clinical remission.
METHODS
Forty children aged 6–18 years with asthma according to ATS
criteria were enrolled at the moment when discontinuation of
ICS was considered because of lack of symptoms for more
than 6 months at a stable dose of ICS (100–400 mg/day
budesonide or equivalent). Children on leukotriene receptor
antagonists were excluded. Atopy was defined as RAST class
2 or higher for at least one airborne allergen. Written
informed consent was obtained and the study was approved
by the medical ethical committee of the Erasmus Medical
Centre.
Study design
This prospective study lasted 26 weeks. During a run-in
period of 2 weeks (from t=22 to t=0) and 2 weeks before
every visit, children recorded cough, wheezing, and dyspnoea
twice daily on a 4 point scale (0–3) on a diary card as used in
previous studies.16 The maximum possible cumulative symp-
tom score was 252. Medication use and peak expiratory flow
(PEF) were recorded twice daily. Children used a peak flow
meter at home (Glaxo Wellcome, Zeist, The Netherlands) and
recorded the personal best value of three attempts in the
morning and evening. Diurnal PEF variability was defined as
the difference between evening and morning values, divided
by the mean of both measurements. At the start of the run-in
period, the inhalation technique was checked and adherence
to ICS treatment was strongly encouraged. Baseline FENO
was measured at t=22 and t=0 weeks. Forced vital
capacity (FVC) and forced expiratory volume in 1 second
(FEV1) before and after bronchodilation were measured at
t=22, 12 and 24 weeks. At t=0 weeks, treatment with ICS
was discontinued in patients with low symptom scores
(below 14), mean PEF variability within 20%, and not
needing rescue medication. FENO was monitored 2, 4, 12, and
24 weeks after withdrawal of ICS. The study design is shown
in table 1.
In cases in whom an upper respiratory tract infection
occurred, follow up visits were postponed for 2 weeks.
Patients were asked to contact the investigator if an
exacerbation occurred, which was defined as asthma sym-
ptoms not responding to the bronchodilator. Subsequently,
Abbreviations: FENO, fractional nitric oxide concentration in exhaled
air; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; ICS, inhaled corticosteroid; PEF, peak expiratory flow
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children were seen and treated by their own paediatric
pulmonologist, not the investigator. A relapse was defined as
more than one exacerbation per month and/or exacerbations
requiring oral or inhaled steroid use and/or need for rescue
bronchodilators on 4 or more days per week for at least two
consecutive weeks and/or mean diurnal PEF variability of
.20% according to the guidelines of the Dutch Paediatric
Respiratory Group.17 The primary end point was relapse. At
the point at which relapse occurred, children dropped out of
the study.
FENO measurements
FENO was measured online with an expiratory flow of 50 ml/s
according to ATS and ERS guidelines.4 5 NO was continuously
sampled with a sampling flow of 175 ml/min and analysed by
a chemiluminescence analyser (Sievers 280 NOA, Boulder,
CO, USA). The analyser was calibrated weekly using 0 and
115 ppb NO certified gases (BOC, Herenthout, Belgium).
Lung function testing
Flow-volume curves were obtained with a dry rolling seal
spirometer (Jaeger, Wu¨rzburg, Germany) according to ATS
guidelines. After maximal inspiration, three reproducible
loops with a maximum variability in FVC of 10% were
obtained. FVC and FEV1 are expressed as percentage
predicted.18
Statistical analysis
FENO values were logarithmically transformed before statis-
tical analyses and the results expressed as geometric means.
FENO at t=0 weeks was used as baseline. For each interval
between two measurements we assessed whether FENO at the
beginning of the interval was predictive for the occurrence of
relapse during the interval. Subsequently, the information
from these four analyses were combined using conditional
logistic regression which relates the probability of relapse in
each period to FENO at the start of this period.
19 Multivariate
analysis was repeated using either FENO or the ratio of FENO
to baseline FENO. FENO at baseline and at the various time
points was compared in patients with and without clinical
relapse using Mann-Whitney U tests. ROC curves for FENO 2
and 4 weeks after discontinuation of ICS were constructed.
The correlation between FENO and clinical and lung function
parameters was assessed using Spearman’s correlation
coefficient.
RESULTS
Of the 40 children included in the study, one dropped out
because of a high symptom score during the run-in period
and two were lost to follow up. The remaining 37 patients (21
boys) had a mean age of 12.2 years (range 7.3–16.9). Data on
the study population are shown in table 2. Twenty nine were
atopic; these children did not differ from non-atopic children
in age, height and weight, nor in pulmonary function tests or
baseline FENO. None of the children used long acting b2
agonists or leukotriene antagonists.
Baseline geometric mean FENO at t=0 was 11.2 ppb (95%
CI 8.5 to 15.3). This did not differ significantly from FENO at
t=22, the start of the run-in period (p=0.67). Intra-
individual variability between values at t=22 and
Table 1 Study design
Time (weeks)
t=22 t=0 t=2 t=4 t=12 t=24
FENO 6 6 6 6 6 6
Diary card 6 6 6 6 6
Spirometry 6 6 6
Symptom scores were obtained during the 2 weeks before each visit. At t=0, inhaled steroids were discontinued.
Table 2 Baseline anthropometric and lung function data
of study population (n = 37 children, 21 boys)
Without relapse
(n = 28)
With relapse
(n = 9)
Age (years) 12.2 (7.3–16.9) 12.3 (10.0–15.8)
Atopy (n) 21 8
Daily dose ICS
(budesonide equivalent) mg
400 (100–400) 200 (100–400)
Height (m) 1.53 (1.30–1.81) 1.52 (1.44–1.66)
Weight (kg) 10.2 (7.3–14.2) 14.8 (8.5–25.8)
FEV1 (% pred) 100 (73–134) 99 (88–109)
FVC (% pred) 102 (66–126) 105 (87–118)
FEV1 (% pred) post* 106 (80–139) 107 (91–119)
FVC (% pred) post* 103 (66–127) 105 (78–118)
PEF (l/s) 383 (195–600) 426 (270–800)
PEF diurnal variabilty (%) 5.6 (1–10) 6.3 (3–11)
Baseline FENO (ppb) 10.5 (7.3–14.2) 14.8 (8.5–25.8)
ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 second;
FVC, forced vital capacity; PEF, peak expiratory flow; FENO, fractional
nitric oxide concentration in exhaled air.
Data are given as mean (range) except for the dose of ICS which is given
as median. FENO is given as geometric mean with 95% confidence
interval. None of the items differed significantly between children with
and without relapse.
*After bronchodilation with 1000 mg terbutaline.
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Figure 1 FENO values in patients with and without an asthma relapse.
For each period (0–2, 2–4, 4–12, and 12–24 weeks) patients were
classified according to whether they relapsed or not in the period
indicated. FENO values were obtained at the start of each period. For
patients without a relapse geometric mean FENO and 95% confidence
intervals are given. The x axis depicts number of weeks after withdrawal
of ICS. One patient relapsed in the first period (0–2 weeks), one between
2 and 4 weeks, six between 4 and 12 weeks, and one after 12 weeks.
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t=0 weeks was considerable (intraclass correlation coeffi-
cient 0.52).
FENO and relapse of asthma
Nine patients (24%), one of whom was non-atopic, had a
clinical relapse after a median of 36 days (range 14–141). Of
these nine patients, five had two exacerbations within
1 month or a single exacerbation requiring oral or inhaled
steroids and four used their bronchodilator as rescue therapy
for >4 days a week during at least two consecutive weeks.
Six children relapsed between 4 and 12 weeks after with-
drawal of ICS; in the periods 0–2 weeks, 2–4 weeks, and 12–
24 weeks, one patient relapsed in each period (fig 1).
Children who experienced an asthma relapse did not differ
in baseline demographic or pulmonary function data
(table 2). There was no difference in initial steroid dose of
children who did or did not relapse (Mann-Whitney U test,
p=0.28), nor was there a significant difference in baseline
geometric mean FENO between the two groups of patients
(14.8 ppb v 10.5 ppb, respectively; ratio 1.4; 95% CI 0.7 to 2.8,
p=0.32). Two weeks after withdrawal of ICS the geometric
mean FENO in children who relapsed thereafter (n=8) was
significantly higher than in those who did not relapse
(35.3 ppb v 15.7 ppb; ratio 2.3; 95% CI 1.2 to 4.1, p=0.01).
The same was true for FENO after 4 weeks without steroids
for the seven children who relapsed after 4 weeks (40.8 ppb
and 15.9 ppb; ratio 2.6; 95% CI 1.3 to 5.1, p=0.009; fig1).
FENO at 4 weeks after withdrawal of ICS predicted relapse
in the forthcoming period (4–12 weeks after withdrawal,
p=0.025). Multivariate logistic regression combining results
of all periods showed that FENO was a better predictor of
asthma relapse (p=0.001) than the FENO ratio (actual FENO
divided by baseline FENO) (p=0.04). For each doubling of
FENO the relapse rate increased by a factor 3.0 (95% CI 1.5 to
7.1). The results were similar when only atopic patients were
analysed.
Two patients were included who later admitted to having
used more than 400 mg budesonide regularly before enrol-
ment. One of them relapsed. If both children were excluded,
multivariate logistic regression still showed that FENO
predicted asthma relapse in the remainder (p=0.003).
ROC curves indicated that a FENO value of 49 ppb 4 weeks
after stopping steroids had the best combination of sensitivity
and specificity for predicting relapse (sensitivity: 71% (95% CI
29 to 96) and specificity 93% (95% CI 76 to 99); fig 2). The
positive and negative predictive values of FENO of 49 ppb
were 71% and 93%, respectively.
The course of FENO in all individuals who experienced a
relapse is shown in fig 3. In patients who did not relapse
there was a general trend for FENO to rise with time from a
geometric mean of 10.2 ppb at the start of the study to
22.2 ppb after 26 weeks of follow up (fig 1). FENO showed an
overall tracking pattern in those who did not relapse.
Correlations between FENO, clinical symptoms, and
pulmonary function tests
The results of pulmonary function tests, atopic state, PEF
variability, cumulative symptom score and use of rescue
medication during the run-in period did not differ between
children with or without a relapse. Cumulative symptom
scores, spirometric data, PEF values, and PEF variability did
not correlate with geometric mean FENO at any time point.
Other parameters and relapse of asthma
Symptom scores, peak flow, diurnal variability in peak flow,
or other lung function tests performed during the run-in
period did not predict asthma relapse.
DISCUSSION
We found that FENO at 2 and 4 weeks after discontinuing ICS
predicted asthma relapse in asthmatic children who were
taken off ICS because of clinical remission. Initial FENO levels
measured while patients were still on ICS were not predictive
of relapse. An FENO of 49 ppb or higher 4 weeks after
discontinuation of ICS had the best combination of sensitiv-
ity (71%) and specificity (93%).
Few other studies have assessed FENO longitudinally after
discontinuation or reduction of ICS, and none of these
included children. Our results are in agreement with the
study by Jones et al11 in which adult asthmatics treated with a
mean daily ICS dose of up to 1600 mg were forced off steroids
and followed for loss of asthma control. In this study, in
contrast to ours, discontinuing steroids was not clinically
indicated, and loss of control occurred earlier, after a median
of 17 days. Their FENO values were much lower, probably due
to the higher flow rate of 250 ml/s used to obtain exhaled air
samples. Lim et al14 performed a similar study in adults and
their preliminary report states that NO in mixed nasal/oral
exhaled air did not predict asthma relapse. However, mixed
expired air is contaminated by high nasal levels of NO which
makes interpretation impossible. Moreover, they defined
relapse as a recurrence of asthma symptoms requiring either
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Figure 2 ROC curve for FENO 4 weeks after discontinuation of inhaled
corticosteroids. The optimal combination of sensitivity and specificity for
identifying children with relapse was for FENO 49 ppb (71% and 93%,
respectively).
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Figure 3 Course of FENO values in nine patients who relapsed. The only
non-atopic patient who experienced a relapse is marked with an
asterisk.
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b2 agonists or ICS. This might well explain any discrepancy
between their findings and ours.
Jatakanon et al20 studied several non-invasive markers of
airway inflammation in asthma exacerbations induced by
forced reduction of ICS doses from more than 800 mg to
200 mg budesonide in adults. FENO at baseline did not predict
loss of asthma control. However, there was a rapid increase in
FENO before exacerbations 2–4 weeks after decreasing
inhaled steroids. Only 15 patients were included in the
study, and this small number could easily lead to non-
significant findings. Furthermore, ICS were not completely
withdrawn, which reduces the possibility of finding a
difference between the groups.
The increases in FENO over time in children who relapsed
were consistent and larger than within-subject baseline
fluctuations. However, the intra-individual variability in
FENO measurements at the beginning and end of our 2 week
run-in period was quite high. Few data are available on long
term within-subject reproducibility of FENO in asthmatic
children. Earlier reports have focused on short term
reproducibility, which is excellent. Kharitonov et al21 found
intraclass correlation coefficients better than 0.90 in adults
and children with and without asthma, with 95% limits of
agreement of about 4 ppb when children were tested
repeatedly within 4 days. Jones et al reported a within-
subject coefficient of variation of FENO measured with a
1 week interval of 10.5%.11 The variability in our study may
be due to the long interval of 2 weeks between FENO
assessments. We also reasoned that inclusion in the study
as such might affect FENO because of better compliance with
ICS during the run-in. This seems unlikely as increased
compliance would lead to a reduction in FENO whereas we
found no significant difference between FENO at t=22 and
t=0, with a trend towards higher levels at t=0. In addition,
ambient NO levels can be a source of variability. However, we
found no relation between ambient NO and FENO, so we
think ambient NO levels do not explain the variability in
FENO.
We included both atopic and non-atopic asthmatic
subjects, reflecting the asthma population in daily practice.
The numbers are too small for a subgroup analysis; only one
non-atopic child relapsed. The patients who did not relapse
without medication showed a wide range of FENO values
(fig 1). In these children no correlation was found between
FENO and symptom scores. As our follow up was 6 months,
we cannot exclude that some of the children might relapse
later. The possible clinical relevance of an increased FENO in
asymptomatic children therefore remains unclear.
What are the implications of these results for clinical
practice? Our findings in this relatively small group of
asthmatic children strongly suggest that FENO measurements
at 2 and 4 weeks after cessation of steroids are helpful for
identifying children in whom relapse of asthma is more likely
to occur and who might benefit from a close follow up.
However, patient numbers in this study are small and more
children who did not relapse had raised FENO levels than
those who did relapse. Larger studies are needed to confirm
the role of FENO in decision making on ICS in asthmatic
children and to calculate more accurately the sensitivity and
specificity of different cut-off levels of FENO.
In conclusion, this is the first study in children showing
that FENO is an early predicting marker of relapse in asthma
after cessation of ICS. Larger studies are now warranted to
substantiate this finding to further define the role of FENO in
this aspect of asthma management.
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